Literature DB >> 3325926

Pharmacokinetics of the newer fluoroquinolones.

J R Brouwers1.   

Abstract

A large number of pharmacokinetic studies have been carried out using 4-quinolones in order to estimate total and renal clearance, to examine tissue penetration, to establish suitable dosage regimens and to determine the influence of kidney and liver impairment on the pharmacokinetic behaviour. Although the quinolones are poorly water soluble over the physiological pH range (6-8) they are well absorbed following oral administration. Ofloxacin is almost completely absorbed and ciprofloxacin has been shown to have an absolute bioavailability of 0.70. Plasma protein binding varies greatly from quinolone to quinolone ranging from about 10% in the case of norfloxacin to more than 90% in the case of nalidixic acid. Penetration of the quinolones into the prostate is generally good. Most quinolones, too, have been shown to penetrate blister fluid rapidly and this model has proved useful in distribution studies. Some quinolones, like ofloxacin, are excreted largely unchanged while others like pefloxacin and acrosoxacin, are almost completely metabolized. Conjugation to very water-soluble glucuronides is not common although other types of metabolites have been shown. Little information appears to have been published on the effect of liver disease on the metabolism of the quinolones. This must be an important consideration for this type of drugs which are subject to hepatic transformation. The pharmacokinetic behaviour of quinolones in patients with impaired renal function has been extensively studied. The interaction of food on the absorption does not seem to be great, there is however evidence of a drug interaction between theophylline and some of the newer quinolones. Sucralfate and antacids containing Mg2+ or (and) Al3+-ions can markedly impair the absorption of quinolone antibiotics.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3325926     DOI: 10.1007/bf02075253

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  20 in total

1.  The diffusion of pefloxacin into bone and the treatment of osteomyelitis.

Authors:  P Dellamonica; E Bernard; H Etesse; R Garraffo
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

2.  The comparative pharmacokinetics of five quinolones.

Authors:  R Wise; D Lister; C A McNulty; D Griggs; J M Andrews
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

3.  Renal elimination of sulfo-ciprofloxacin, a new metabolite of ciprofloxacin.

Authors:  K Borner; H Lode; G Höffken
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

4.  The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers.

Authors:  R Wolf; R Eberl; A Dunky; N Mertz; T Chang; J R Goulet; J Latts
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

5.  Transfer of ciprofloxacin to bile and determination of biliary metabolites in humans.

Authors:  H Tanimura; S Tominaga; F Rai; H Matsumoto
Journal:  Arzneimittelforschung       Date:  1986-09

Review 6.  Drug interactions of ciprofloxacin with other non-antibiotic agents.

Authors:  E Rubinstein; S Segev
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

7.  Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function.

Authors:  D B Webb; D E Roberts; J D Williams; A W Asscher
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

Review 8.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

9.  Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers.

Authors:  A M Frydman; Y Le Roux; M A Lefebvre; F Djebbar; J B Fourtillan; J Gaillot
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

10.  Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses.

Authors:  T Bergan; S B Thorsteinsson; R Solberg; L Bjornskau; I M Kolstad; S Johnsen
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

View more
  2 in total

1.  Decreased ciprofloxacin absorption with concomitant administration of ferrous fumarate.

Authors:  J R Brouwers; H J Van der Kam; J Sijtsma; J H Proost
Journal:  Pharm Weekbl Sci       Date:  1990-10-19

Review 2.  Drug interactions with quinolone antibacterials.

Authors:  J R Brouwers
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.